Skip to main content
Fig. 2 | Virology Journal

Fig. 2

From: Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation

Fig. 2

Percentages of HLA-A*0201/EBV-BMLF1-GLC-specific CD8+ T cells in patients at + 30, + 60, and + 90 days after haplo-HSCT and in healthy controls. Data are expressed as the means ± standard deviations. The recovery of CD8+ T cells against EBV specific epitope BMLF1-GLC as measured by pentamer technology. Four group are shown on the panel. The percentages of HLA-A*0201/EBV-BMLF1-GLC-specific CD8+ T cells in patients at + 30, + 60, and + 90 days after haplo-HSCT and in healthy controls are presented

Back to article page

Virology Journal

ISSN: 1743-422X